KMT2A and acute myeloid leukemia: Age, sex, de novo AML, AML at first diagnosis, FAB type M4/M5, cytogenetic risk, ELN risk, normal karyotype, NPM1 mutation status, FLT3-ITD mutation status, presence of a FLT3-TKD, presence of a MLL-PTD, WBC, platelet count, haemoglobin level, bone marrow (BM) blasts and peripheral blood (PB) blasts, PTT, fibrinogen, antithrombin III, troponin, lactate levels, D-dimer and neurologic derogation displayed no significant effect on EDd7.